Treatment with insulin and its analogs in pregnancies complicated by diabetes

Diabetes Care

Volumn 30, Issue SUPPL. 2, 2007, Pages

  Jovanovic, Lois ^a   Pettitt, David J ^a  

^a SANSUM DIABETES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO;

ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; PREGNANCY; PREGNANCY DIABETES MELLITUS; RISK FACTOR;

FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PREGNANCY; PREGNANCY IN DIABETICS; PREGNANCY OUTCOME; RECEPTOR, IGF TYPE 1;

EID: 34447118711     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-s220     Document Type: Article

References (44)

1. Pedersen J: Course of diabetes during pregnancy. Acta Endocrinol 9:342-347, 1952
2. Jovanovic L, Peterson CM, Saxena BB, Dawood MY, Saudek CD: Feasibility of maintaining normal glucose profiles in insulin-dependent pregnant diabetic women. Am J Med 68:105-112, 1980
3. de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT: Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 333:1237-1241, 1995
4. Jovanovic-Peterson L, Peterson CM, Reed GF, Metzger BE, Mills JL, Knopp RH, Aarons JH: Maternal postprandial glucose levels and infant birth weight: the Diabetes In Early Pregnancy Study. Am J Obstet Gynecol 164:103-111, 1991
5. Jovanovic L: What is so bad about a big baby? (Editorial) Diabetes Care 24:1317-1318, 2001
6. Challier JC, Haugel S, Desmaizieres V: Effects of insulin on glucose uptake and metabolism in the human placenta. J Clin Endocrinol Metab 62:803-807, 1986
7. Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G: Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care 26:1390-1394, 2003
8. Menon RK, Cohen RM, Sperling MA, Cutfield WS, Mimouni F, Khoury JC: Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus: its role in fetal macrosomia. N Engl J Med 323:309-315, 1990
9. Jovanovic L, Kitzmiller JL, Peterson CM: Randomized trial of human versus animal species insulin in diabetic pregnant women: improved glycemic control, not fewer antibodies to insulin, influences birth weight. Am J Obstet Gynecol 167:1325-1330, 1992
10. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, DiMarchi R: Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 46:265-270, 1997
11. Fineberg SE, Rathbun MJ, Hufferd S, Fingerb NS, Spradlin CT, Galloway JA, Frank B: Immunologic aspects of human proinsulin therapy. Diabetes 37:276-280, 1988
12. Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S: Immunologic effects of insulin lispro [Lys(B23), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 45:1750-1754, 1996
13. Jovanovic L, Ilic S, Pettitt DJ, Hugo K, Gutierrez M, Bowsher RR, Bastyr EJ: The metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 22:1422-1426, 1999
14. Bhattacharyya A, Brown S, Hughes S, Vice PA: Insulin lispro and regular insulin in pregnancy. QJM 94:255-260, 2001
15. Calle-Pascual AL, Bagazgoitia J, Calle JR, Charro A, Maranes JP: Use of insulin lispro in pregnancy. Diabetes Nutr Metab 13:173-177, 2003
16. Ozcan T, Karne A, Murphy J, Nickless N, Magriples U, Jones DC: Does lispro improve blood glucose control and birth weight? Obstet Gynecol 97:S41, 2001
17. Balsells M, Corcoy R, Mauricio D, Morales J, Garcia-Patterson A, Carreras G, Puig-Domingo M, de Leiva A: Insulin antibody response to a short course of human insulin therapy in women with gestational diabetes. Diabetes Care 20:1172-1175, 1997
18. Diamond T, Kormas N: Possible adverse fetal effects of insulin lispro. N Engl J Med 337:1009, 1997
19. Anderson J, Bastyr E, Wishner K: Response to Diamond and Kormas. N Engl J Med 337:1009-1012, 1997
20. Wyatt JW, Frias JL, Hoyme HE, Jovanovic L, Kaaja R, Brown F, Garg S, Lee-Parritz A, Seely EW, Kerr L, Mattoo V, Tan M, IONS Study Group: Congenital anomaly rate in offspring of pre-gestational diabetic women treated with insulin lispro during pregnancy. Diabet Med 21:2001-2007, 2004
21. Heinemann L, Kapitza C, Starke AA, Heise T: Time-action profile of the insulin analog B28Asp. Diabet Med 13:683-684, 1996
22. Home PD, Lindholm A, Hylleberg B, Round P: Improved glycemic control with insulin aspart: a multi-center randomized double-blind crossover trial in type 1 diabetic patients: UK Insulin Aspart Study Group. Diabetes Care 21:1904-1909, 1998
23. Home PD, Barriocanal L, Lindholm A: Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analog, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 55:199-203, 1999
24. NovoLog Product Labeling Physicians' Desk Reference, 58th ed. Montvale, NJ, Thomson PDR, 2004, p. 2355-2359
25. Pettitt DJ, Ospina P, Kolaczynski J, Jovanovic L: Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care 26:183-186, 2003
26. Jovanovic L, Howard C, Pettitt D, Zisser H, Ospina P: Insulin aspart vs. regular human insulin in basal/bolus therapy for patients with gestational diabetes mellitus: safety and efficacy. Diabetologia 48 (Suppl. 1):A317-A318, 2005
27. Hod M, for the Novorapid Insulin Trial of the Safety and Efficacy of Insulin Aspart for the Treatment of Type 1 Diabetic Women during Pregnancy: Study design. Presented at the European Association for the Study of Diabetes, 2005
28. Devlin JT, Hothersail L, Wilkis JL: Use of insulin glargine during pregnancy in a type 1 diabetic woman. Diabetes Care 25:1095-1096, 2002
29. Holstein A, Plashke A, Egberts EH: Use of insulin glargine during embryogenesis in a pregnant women with type 1 diabetes. Diabet Med 20:779-780, 2003
30. Di Gianni G, Volpe L, Lencioni C, Charzianagnostou K, Cuccura I, Ghio A, Benzi L, Del Prado S: Use of insulin glargine during the first few weeks of pregnancy in five type 1 diabetic women. Diabetes Care 28:982-983, 2005
31. Wooldrenrink JM, van Loon AJ, Storms F, De Heide L, Hoogenberg K: Use of insulin glargine during pregnancy in seven type 1 diabetic women. Diabetes Care 28:2394-2395, 2005
32. Hamilton-Wessler M, Ader M, Dea M, Moore D, Jorgensen PN, Markussen J, Bergman RN: Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia 42:1254-1263, 1999
33. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, Markussen J: Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312:725-731, 1995
34. Whittingham JL, Havelund S, Jonassen I: Crystal structure of a prolonged-acting insulin with albumin-binding properties. Biochemistry 36:2826-2831, 1997
35. Home PD, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E, Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group: Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 27:1081-1087, 2004
36. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA: Insulin analogs (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47:622-629, 2004
37. Druckmann R, Rohr UD: IGF-1 in gynaecology and obstetrics: update 2002. Maturitas 41 (Suppl. 1):S65-S83, 2002
38. Mandl M, Haas J, Bischof P, Nohammer G, Desoye G: Serum-dependent effects of IGF-I and insulin on proliferation and invasion of human first trimester trophoblast cell models. Histochem Cell Biol 117:391-399, 2002
39. Lacroix MC, Guibourdenche J, Frendo JL, Muller F, Evain-Brion D: Human placental growth hormone: a review. Placenta 23 (Suppl. A):S87-S94, 2002
40. De Meyts P, Whittaker J: Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1:769-783, 2002
41. Drejer K: The bioactivity of insulin analogs from in vitro receptor binding to in vivo glucose uptake. Diabete Metab Rev 8:259-285, 1992
42. Bahr M, Kolter T, Seipke G, Eckel J: Growth promoting and metabolic activity of the human insulin analog [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 320:259-265, 1997
43. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005, 2000
44. Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR: Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 86:5838-5847, 2001